Signatures of Immune Reprogramming in Anti-Cd52 Therapy of MS: Markers for Risk Stratification and Treatment Response

Neurological Research and Practice
doi 10.1186/s42466-019-0045-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy